Melanotan II vs Triptorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Melanotan II
Melanotan II (MT-II) is a cyclic lactam analog of alpha-melanocyte stimulating hormone (α-MSH) that acts as a potent, non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R, MC5R). Developed at the University of Arizona in the late 1980s, it produces eumelanin-driven skin darkening (tanning) via MC1R, sexual arousal and spontaneous erections via MC4R, and appetite suppression via MC3R/MC4R. Bremelanotide (PT-141) — now FDA-approved for female sexual dysfunction — was derived from Melanotan II.
Full profileTriptorelin
Potent synthetic GnRH agonist approximately 100× more potent than native GnRH. Used clinically for prostate cancer, endometriosis, and precocious puberty via sustained suppression. A single low dose (100mcg IM) is studied as a 'PCT restart' strategy that exploits the initial LH/FSH flare before receptor desensitization sets in.
Full profile| Melanotan II | Triptorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | MT-II, MTII, Cyclo[Nle4,D-Phe7]-α-MSH | GnRH agonist, Decapeptyl, Trelstar, D-Trp6-LHRH |
| Evidence | Research-stage | Research-stage |
| Dosing range | 250mcg–1000mcg mcg, Daily during loading phase; 2–3x weekly for maintenance | 50mcg–200mcg mcg, Single-dose for PCT restart; every 2–4 weeks for sustained suppression (clinical) |
| Administration | Subcutaneous injection (most common), Intranasal (less effective, lower bioavailability) | Intramuscular injection, Subcutaneous injection |
| Key side effects | Nausea (most common — especially first 30–60 minutes post-injection), Facial flushing, Spontaneous erections (males — often unwanted at higher doses), Fatigue / yawning post-injection | Initial testosterone surge followed by suppression (with repeated dosing), Hot flashes, Decreased libido, Bone density loss (long-term repeated dosing) |
| Cited sources | 3 references | 2 references |
Key differences
- Administration: Melanotan II — Subcutaneous injection (most common), Intranasal (less effective, lower bioavailability); Triptorelin — Intramuscular injection, Subcutaneous injection.
- Frequency: Melanotan II is typically Daily during loading phase; 2–3x weekly for maintenance; Triptorelin is Single-dose for PCT restart; every 2–4 weeks for sustained suppression (clinical).
- Research depth: this profile cites 3 sources for Melanotan II vs 2 for Triptorelin.
How each works
Melanotan II
Melanotan II's broad melanocortin receptor agonism produces a constellation of effects across multiple systems. MC1R activation in melanocytes upregulates tyrosinase, the rate-limiting enzyme in melanin synthesis, producing UV-independent skin darkening. MC4R activation in the CNS and spinal cord drives sexual arousal and erectogenic effects more potent than most PDE5 inhibitors, and also produces appetite suppression and reduced food intake (the same pathway exploited by weight-loss drugs targeting the melanocortin system). MC3R activation contributes to energy homeostasis effects.
Triptorelin
Triptorelin produces a biphasic response: an initial agonist surge of LH and FSH (the 'flare effect') followed by complete pituitary desensitization with continued use. The single-dose PCT protocol leverages only the initial flare to jumpstart testosterone production. Clinical data supports LH surges of 10–20× baseline within hours of the first dose.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.